Understanding how ATG2 helps cells recycle and maintain health
ATG2 transfers lipids from ER exit site membranes to directly expand the growing autophagosome
This study is looking at how a protein called ATG2 helps cells clean up damaged parts, which is important for keeping our cells healthy and could lead to new treatments for conditions like Alzheimer's and ALS.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10904711 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called ATG2 in the process of autophagy, which is crucial for cellular health and is linked to aging and neurodegenerative diseases like Alzheimer's and ALS. The study aims to understand how ATG2 transfers lipids to help form autophagosomes, which are essential for removing damaged cellular components. By exploring the mechanisms of lipid delivery and autophagosome formation, the research seeks to uncover new insights into how these processes can be improved, particularly in aging cells. Patients may benefit from findings that could lead to new therapeutic strategies for neurodegenerative diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing neurodegenerative diseases such as Alzheimer's or ALS, particularly those affected by aging-related cellular decline.
Not a fit: Patients with acute conditions unrelated to neurodegeneration or those not experiencing age-related cellular decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance cellular health and potentially slow down the progression of neurodegenerative diseases.
How similar studies have performed: Other research has shown promising results in understanding autophagy and its implications for neurodegenerative diseases, indicating that this approach has potential for significant breakthroughs.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Fuller, Devin — Yale University
- Study coordinator: Fuller, Devin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.